New target pathway for cancer therapy

癌症治疗的新靶点途径

• 批准号: nhmrc : 1098960
• 负责人: A/Pr Michele Teng
• 金额: $ 50.69万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/new-target-pathway-cancer-therapy/662410
• 关键词: New; target; pathway; cancer; therapy

There is an unmet medical need to develop new therapies that are safer and potentially allow the treatment of a broader range of cancers. Inhibiting the immune checkpoints TIGIT and CD96 represents an opportunity that may parallel and indeed complement the activity and impact of other lymphocyte checkpoint inhibitors in human cancer (eg. PD1/PD-L1). While testing these as targets in mice we will also learn more about their ligand CD155 and their expression in human tumors.

开发更安全且有可能治疗更广泛癌症的新疗法的医疗需求尚未得到满足。抑制免疫检查点 TIGIT 和 CD96 代表了一个机会，可以与人类癌症中其他淋巴细胞检查点抑制剂（例如 PD1/PD-L1）的活性和影响平行甚至补充。在小鼠中测试这些作为靶点的同时，我们还将更多地了解它们的配体 CD155 及其在人类肿瘤中的表达。